Blood Coagulation Tubes Market Analysis & Forecast: 2026-2033

Blood Coagulation Tubes Market Size and Forecast – 2026 to 2033

The Blood Coagulation Tubes Market is anticipated to grow at a CAGR of 7.1% with USD 2.6 Bn share in 2026 and is expected to reach USD 3.7 Bn in 2033. Rising demand for accurate coagulation testing, higher diagnostic testing volumes, and expanding hospital and laboratory infrastructure are driving the Blood Coagulation Tubes Market. Coagulation tests, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen, are routinely used in pediatric practice to assess bleeding and thrombotic disorders, preoperative coagulation status, and anticoagulant therapy.

Key Takeaways

• 3.8% citrate solution hold the largest market share of 53.6% in 2026 owing to its growing demand for coagulation testing.
• Hospitals acquired the prominent market share of 39.7% in 2026 owing to the increasing prevalence of bleeding and clotting disorders. The global prevalence of diagnosed bleeding disorders increased from 2.75 per 100,000 people in 2014 to approximately 3.75 per 100,000 in 2025.
• North America is expected to acquire the dominant share of 42.6% in 2026 owing to its rising surgical and emergency-care activity. In the United States, approximately 1 in 9 people living in households reported undergoing at least one surgical procedure in 2023.

Current Events and Their Impact on the Blood Coagulation Tubes Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Why is 3.8% citrate solution Acquiring the Largest Market Share?

3.8% citrate solution hold the largest market share of 53.6% in 2026. The 3.8% citrate solution segment in the Blood Coagulation Tubes Market benefits from established use in specific coagulation and specialized laboratory testing applications. Laboratories that validate this citrate concentration and establish appropriate reference intervals continue to use these tubes for reliable anticoagulated plasma collection. Hospitals and diagnostic laboratories also sustain demand through routine and specialized coagulation testing. However, laboratories use 3.8% citrate more selectively because current guidelines generally favor lower citrate concentrations for routine coagulation testing.

Which End User segment dominates the market? 

To learn more about this report, Request Free Sample

Hospitals acquired the prominent market share of 39.7% in 2026. Hospitals fuel the Blood Coagulation Tubes Market by increasing coagulation testing across emergency departments, surgical units, critical care, and inpatient services. Healthcare professionals use these tubes to collect blood samples for PT, aPTT, fibrinogen, and D-dimer tests, helping diagnose and monitor bleeding and clotting disorders. Growing anticoagulant use, expanding hospital laboratory capabilities, and stronger focus on accurate preanalytical practices further boost demand. Regular diagnostic testing also drives consistent and recurring consumption of blood coagulation tubes.

Blood Coagulation Tubes Market Trends

• Rising demand for coagulation testing: Increasing use of PT, aPTT, D-dimer, fibrinogen, and other coagulation tests supports the diagnosis and monitoring of bleeding and thrombotic disorders, strengthening demand for blood coagulation tubes. The CDC estimates that venous thromboembolism (VTE) affects up to 900,000 people annually in the United States, highlighting the substantial clinical need for blood-clot evaluation and management.
• Expansion of hospital and diagnostic laboratory infrastructure: Growing access to laboratory services expands coagulation testing across hospitals, emergency departments, clinics, and independent laboratories, supporting recurring consumption of blood coagulation tubes. CMS maintains and updates the Clinical Laboratory Fee Schedule (CLFS) for Medicare-covered laboratory services; the 2026 CLFS includes more than 2,200 records, reflecting the broad scope of reimbursed clinical laboratory testing.
• Advancements in blood collection tube technology: Manufacturers are developing collection tubes with improved specimen handling, stopper designs, vacuum performance, and anticoagulant control to support reliable coagulation testing. Fact: FDA-cleared coagulation collection products include 3.2% sodium-citrate tubes, demonstrating continued regulatory emphasis on standardized anticoagulant concentrations for coagulation specimen collection.

Regional Insights 

To learn more about this report, Request Free Sample

North America dominates owing to presence of major diagnostic and medical-device manufacturers

North America is expected to acquire the dominant share of 42.60% in 2026. North America’s Blood Coagulation Tubes Market benefits from advanced healthcare infrastructure, substantial coagulation testing volumes, and widespread use of automated laboratory technologies. Healthcare providers increasingly diagnose and monitor cardiovascular, bleeding, and thrombotic disorders, which drives demand for coagulation testing and anticoagulation monitoring. Hospitals and clinical laboratories prioritize fast, accurate, and standardized testing, increasing the use of reliable coagulation tubes. Furthermore, investments in laboratory modernization, point-of-care diagnostics, and specialized hemostasis services continue to strengthen regional market demand. In January 2026, Sysmex America launched the CN-9000 Automated Hemostasis Solution, a modular system that supports up to three CN-3000 or CN-6000 coagulation analyzers and an optional integrated tube sorter and archiver for high-volume laboratories.

Asia Pacific Blood Coagulation Tubes Market Trends

The Asia Pacific blood coagulation tubes market is driven by expanding healthcare infrastructure, rising diagnostic testing, and increasing hospital investments. Growing rates of cardiovascular diseases, bleeding disorders, diabetes, and cancer boost demand for coagulation testing. Cardiovascular diseases (CVDs) are the leading cause of death in India, accounting for approximately 25%–28% of all deaths. Aging populations and increasing surgical procedures further support routine blood analysis. Government healthcare programs, preventive screening, private diagnostic laboratories, and automated testing systems are also expanding across the region, strengthening demand for efficient and reliable blood coagulation tubes.

United States Blood Coagulation Tubes Market Trends

In the United States, demand for blood coagulation tubes is rising as healthcare providers conduct more tests for cardiovascular diseases, thrombosis, bleeding disorders, and preoperative care. Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), affects an estimated 300,000–900,000 people in the United States annually. Hospitals, diagnostic laboratories, and outpatient centers are also expanding their use of these tubes. Manufacturers are further supporting market growth by improving vacuum collection systems, citrate formulations, sample stability, and safety features, helping laboratories achieve accurate and efficient testing. In July 2026, Teleflex received FDA approval for EZPLAZ Freeze-Dried Plasma, expanding plasma replacement options for adults with bleeding conditions when conventional plasma products are unavailable.

Japan Blood Coagulation Tubes Market Trends

Japan’s Blood Coagulation Tubes Market benefits from its aging population, rising chronic and cardiovascular diseases, and growing demand for routine coagulation testing. Hospitals and clinical laboratories increasingly perform diagnostic tests, boosting tube consumption. Japan’s emphasis on preventive healthcare and early disease detection further supports regular blood testing. Manufacturers improve laboratory efficiency through advanced vacuum collection systems, automation, and specialized tubes. Strict healthcare standards also drive demand for safe, reliable, and high-quality coagulation tubes across Japan’s healthcare sector. In February 2026, Q-Sera launched its patented evacuated blood collection technology through Terumo Corporation’s VenoJect II RAPClot blood collection tubes in Japan.

Who are the Major Companies in Blood Coagulation Tubes Industry

Some of the major key players in Blood Coagulation Tubes are Medical Expo, Ajosha BioTeklik Pvt. Ltd., CML Biotech Pvt. Ltd., New MicroMed International Pvt. Ltd., Greiner BioOne, Gosselin, FL Medical, and Advacare Pharma.

Key News

• In December 2024, HORIBA launched the Yumizen H550E, H500E CT, and H500E OT hematology analyzers, enabling CBC/DIFF and ESR testing from whole blood in 60 seconds for small- to mid-throughput laboratories.

Market Report Scope

Analyst Opinion

• Blood coagulation testing is a clinical necessity, not a discretionary diagnostic trend. In my view, demand for coagulation tubes will remain structurally resilient because tests such as PT/INR and aPTT directly guide anticoagulant management, bleeding-risk assessment, and surgical decision-making. The scale of anticoagulant use reinforces this need: more than 8 million patients in the U.S. receive warfarin annually, creating a sustained requirement for reliable blood collection and coagulation testing.
• The expansion of anticoagulant therapy is a major volume driver for coagulation tubes. Direct oral anticoagulants have increasingly replaced warfarin for conditions such as atrial fibrillation and venous thromboembolism, while routine coagulation testing remains essential in emergency, perioperative, and complex-care settings. Atrial fibrillation affects more than 50 million people globally, strengthening the underlying need for coagulation assessment and monitoring across hospitals and diagnostic laboratories.
• Pre-analytical accuracy is becoming the key competitive differentiator, and this favors high-quality citrate tubes. Coagulation assays are particularly sensitive to incorrect blood-to-anticoagulant ratios, underfilling, clotted specimens, and improper handling. Standard coagulation tubes use a 9:1 blood-to-sodium-citrate ratio, making fill accuracy critical to reliable results. From an analyst perspective, laboratories are therefore more likely to prioritize tubes with consistent vacuum performance, precise citrate volume, and strong specimen integrity rather than selecting products solely on price.
• Automation is shifting demand toward standardized, laboratory-compatible coagulation tubes. High-volume laboratories increasingly integrate automated pre-analytical and analytical systems, making tube dimensions, barcode compatibility, cap design, and specimen consistency operational requirements. For example, automated coagulation platforms from major diagnostic manufacturers process PT, aPTT, fibrinogen, and D-dimer testing at scale.
• The strongest opportunity lies in specialized and high-reliability tubes rather than undifferentiated commodity products. Increasing use of molecular coagulation tests, thrombophilia investigations, D-dimer testing, and specialized hemostasis assays is raising the importance of specimen quality. Manufacturers that combine low tube variability, reliable citrate concentration, automation compatibility, and stringent quality control will capture more laboratory preference than suppliers competing primarily through lower pricing.

Market Segmentation

• By Citrate Concentration (Revenue, USD Bn, 2021-2033)
  • 3.8% citrate solution
  • 3.2% citrate solution
• By End User (Revenue, USD Bn, 2021-2033)
  • Diagnostic Centers
  • Government
  • Hospitals
  • Medical Practitioners
  • Others
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research interviews

• Clinical laboratory directors and coagulation laboratory specialists
• Pathologists and hematologists
• Hospital procurement and laboratory purchasing managers
• Phlebotomy and specimen-collection professionals
• Blood collection tube manufacturers and distributors
• Diagnostic laboratory equipment and automation specialists

Databases

• U.S. Food and Drug Administration (FDA) medical device databases
• National Institutes of Health (NIH) / PubMed
• Centers for Disease Control and Prevention (CDC) databases
• World Health Organization (WHO) databases
• U.S. National Library of Medicine (NLM)
• Eurostat healthcare and demographic databases
• OECD Health Statistics
• Japan Ministry of Health, Labour and Welfare (MHLW) databases

Magazines

• Medical Laboratory Observer
• CAP Today
• Lab Manager
• Medical Design & Outsourcing
• Diagnostic and laboratory technology publications

Journals

• Journal of Thrombosis and Haemostasis
• International Journal of Laboratory Hematology
• Thrombosis Journal
• Blood Coagulation & Fibrinolysis
• Clinical Chemistry and Laboratory Medicine
• American Journal of Clinical Pathology
• Journal of Clinical Laboratory Analysis
• Research and Practice in Thrombosis and Haemostasis

Newspapers

• The New York Times
• The Wall Street Journal
• The Guardian
• Reuters
• Financial Times
• Nikkei Asia

Associations

• Clinical and Laboratory Standards Institute (CLSI)
• International Council for Standardization in Haematology (ICSH)
• International Society on Thrombosis and Haemostasis (ISTH)
• College of American Pathologists (CAP)
• European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
• American Society for Clinical Pathology (ASCP)
• World Federation of Hemophilia (WFH)

Public Domain sources

• U.S. Food and Drug Administration (FDA) medical device records and safety communications
• National Institutes of Health (NIH) and PubMed publications
• Centers for Disease Control and Prevention (CDC) health statistics
• World Health Organization (WHO) reports and datasets
• Japan Ministry of Health, Labour and Welfare (MHLW) statistics and regulatory information
• European Medicines Agency (EMA) public documents
• European Commission medical-device regulatory resources
• Clinical and Laboratory Standards Institute (CLSI) publicly available guidance
• International Council for Standardization in Haematology (ICSH) recommendations
• National health ministry and government laboratory statistics
• Public clinical-trial registries and peer-reviewed scientific literature

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years